|
🐜
|
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms
21 auth.
R. Cooper-DeHoff,
M. Niemi,
L. Ramsey,
Jasmine A. Luzum,
E. Tarkiainen,
R. Straka,
L. Gong,
S. Tuteja,
R. Wilke,
M. Wadelius,
...
Eric A. Larson,
D. Roden,
T. Klein,
S. Yee,
R. Krauss,
R. Turner,
L. Palaniappan,
A. Gaedigk,
K. Giacomini,
K. Caudle,
D. Voora
|
7 |
2022 |
7
🐜
|
|
🐜
|
Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype‐Guided Antiplatelet Therapy
26 auth.
P. Empey,
J. Stevenson,
S. Tuteja,
K. Weitzel,
D. Angiolillo,
A. Beitelshees,
James C. Coons,
Julio D. Duarte,
Francesco Franchi,
L. Jeng,
Julie A. Johnson,
R. Kreutz,
N. Limdi,
Kristin A. Maloney,
Aniwaa Owusu Obeng,
...
J. Peterson,
Natasha J. Petry,
V. Pratt,
F. Rollini,
S. Scott,
T. Skaar,
M. Vesely,
G. Stouffer,
R. Wilke,
L. Cavallari,
Craig R. Lee
|
6 |
2018 |
6
🐜
|
|
🦁
|
THE EFFECT OF GUT METABOLISM ON TACROLIMUS BIOAVAILABILITY IN RENALTRANSPLANT RECIPIENTS1,2
S. Tuteja,
R. Alloway,
Julie A. Johnson,
A. Gaber
|
6 |
2001 |
6
🦁
|
|
🐢
|
Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users
11 auth.
Catherine Chanfreau-Coffinier,
L. Hull,
J. Lynch,
S. Duvall,
S. Damrauer,
F. Cunningham,
...
B. Voight,
M. Matheny,
D. Oslin,
M. Icardi,
S. Tuteja
|
6 |
2019 |
6
🐢
|
|
🐜
|
Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016
7 auth.
E. Dayoub,
M. Seigerman,
S. Tuteja,
Taisei J. Kobayashi,
D. Kolansky,
Jay Giri,
...
P. Groeneveld
|
6 |
2018 |
6
🐜
|
|
🐜
|
Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta‐Analysis
9 auth.
D. Sawinski,
J. Trofe‐Clark,
J. Trofe‐Clark,
B. Leas,
Stacey Uhl,
S. Tuteja,
...
Janice Kaczmarek,
Benjamin French,
C. Umscheid
|
6 |
2016 |
6
🐜
|
|
🐜
|
HSP27 in signal transduction and association with contractile proteins in smooth muscle cells.
8 auth.
A. Ibitayo,
J. Sladick,
S. Tuteja,
O. Louis-Jacques,
Hirotaka Yamada,
G. Groblewski,
...
M. Welsh,
K. Bitar
|
6 |
1999 |
6
🐜
|
|
🐜
|
The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real‐World Setting
27 auth.
L. Cavallari,
A. Beitelshees,
K. Blake,
Lynn G. Dressler,
Julio D. Duarte,
Amanda Elsey,
J. Eichmeyer,
P. Empey,
J. Franciosi,
J. Hicks,
A. Holmes,
Linda J. B. Jeng,
Craig R. Lee,
J. Lima,
N. Limdi,
...
J. Modlin,
A. Obeng,
Natasha J. Petry,
V. Pratt,
T. Skaar,
S. Tuteja,
D. Voora,
M. Wagner,
K. Weitzel,
R. Wilke,
Joshua F. Peterson,
Julie A. Johnson
|
6 |
2017 |
6
🐜
|
|
🦁
|
Community pharmacists' attitudes towards clinical utility and ethical implications of pharmacogenetic testing.
S. Tuteja,
K. Haynes,
Cara Zayac,
J. E. Sprague,
B. Bernhardt,
R. Pyeritz
|
6 |
2013 |
6
🦁
|
|
🦁
|
The Gut Microbiome and Response to Cardiovascular Drugs.
S. Tuteja,
J. Ferguson
|
6 |
2019 |
6
🦁
|
